ArticleBMC oral health2025
ANO5 p.I616F variant drives florid cemento-osseous dysplasia by disrupting transmembrane domain structure.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTo date, genetic studies on florid cemento-osseous dysplasia (FCOD) remain limited. This study aimed to elucidate the clinical features and genetic basis of FCOD in Chinese populations, with particular emphasis on identifying pathogenic ANO5 variants and their mechanistic contributions to disease development.
methodsClinical data from 17 FCOD patients diagnosed between May 2015 and December 2024 at Kunming Medical University Affiliated Stomatological Hospital were retrospectively analyzed. Whole-exome sequencing was performed on a familial cohort (8 individuals). Identified variants were validated using Sanger sequencing. Pathogenicity was predicted via SIFT, PolyPhen-2, and MutationTaster, while protein structural alterations were modeled with AlphaFold 2. Histological assessment included H&E staining, Masson trichrome, RUNX2 immunohistochemistry, and TRAP staining to quantify osteoclastic activity.
resultsAmong the 17 FCOD patients included in this study, 10 (58.8%) were female, with a mean age of 47.4 ± 13.2 years. Genetic analysis identified Anoctamin 5 (ANO5) variants in five cases, including a novel variant (p.I616F). Pedigree analysis confirmed that p.I616F was a heterozygous variant, and bioinformatics prediction indicated its likely pathogenicity. Structural modeling further demonstrated that this variant disrupted the α-helix of ANO5 and altered the catalytic site’s conformation. Additionally, histological evaluation revealed significantly elevated RUNX2 expression and increased osteoclast activity in the jawbone tissues of FCOD patients.
conclusionThis study provides the first evidence that ANO5 variants (particularly p.I616F) may represent key genetic factors contributing to FCOD development in the Chinese population. The mutation likely disrupts the α-helical structure of ANO5 protein, impairing its catalytic function and potentially dysregulating bone remodeling processes in FCOD pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.